Androgen Replacement Therapy

Androgen Replacement Therapy Market Outlook

The global androgen replacement therapy market is projected to reach approximately USD 4.9 billion by 2035, growing at a CAGR of 6.2% during the forecast period from 2025 to 2035. This growth can be attributed to an increasing aging population, rising instances of hypogonadism, and a growing awareness regarding the benefits of androgen therapy among healthcare professionals and patients alike. Additionally, advancements in medical technology and the development of more effective and safe androgen formulations have further fueled this market's expansion. The rising prevalence of lifestyle diseases, including obesity and diabetes, which can lead to hormonal imbalances, is also creating a demand for androgen replacement therapies across various demographics. Moreover, continuous research and development to enhance the administration and effectiveness of these therapies are expected to significantly contribute to market growth.

Growth Factor of the Market

The androgen replacement therapy market is witnessing a surge in growth primarily due to the increasing prevalence of testosterone deficiency among men, particularly as they age. The awareness about health conditions related to low testosterone levels, such as osteoporosis, cardiovascular diseases, and diminished quality of life, has prompted more individuals to seek treatment options. Furthermore, a growing number of healthcare professionals are advocating for testosterone replacement therapy as a viable treatment solution for various conditions, including hypogonadism and andropause. The emergence of online platforms for health consultations and medications has also made it easier for patients to access treatments, significantly boosting market dynamics. Additionally, the rise of telemedicine and digital health technologies have increased the efficiency of diagnosis and treatment delivery, further accelerating the market's growth trajectory.

Key Highlights of the Market

• The global androgen replacement therapy market is expected to grow significantly, driven by the increasing prevalence of testosterone deficiency.
• Technological advancements in drug delivery systems and formulations are enhancing the efficacy of treatments.
• The online pharmacy segment is witnessing rapid growth due to the increasing demand for convenient medication access.
• Men aged 30 years and older are increasingly seeking treatments, expanding the target demographic.
• Regulatory approvals for new therapies are creating a conducive environment for market expansion.

By Product Type

Testosterone Replacement Therapy:

Testosterone Replacement Therapy (TRT) remains the most prominent segment within the androgen replacement therapy market. It involves the administration of testosterone to alleviate symptoms associated with low testosterone levels, such as fatigue, reduced libido, and muscle mass. TRT is available in various forms, including injections, transdermal patches, and gels, providing flexibility to patients in choosing the most suitable method for their lifestyle. The growing acceptance and awareness of TRT's benefits among healthcare providers and patients have significantly contributed to its robust market share. Furthermore, ongoing research into optimized dosing protocols and formulations continues to support the uptake of TRT in clinical practice.

DHEA Replacement Therapy:

DHEA (Dehydroepiandrosterone) replacement therapy has gained traction as an alternative approach for managing hormonal imbalances, particularly for individuals who may not require full testosterone replacement. DHEA serves as a precursor hormone, converting into testosterone and estrogen in the body, thus helping in balancing hormone levels. The therapeutic applications of DHEA include improved energy levels, enhanced mood, and potential benefits in sexual function. As more research highlights the positive effects of DHEA, its adoption in clinical settings has been on the rise, contributing to its growing market segment.

Androstenedione Replacement Therapy:

Androstenedione, a steroid hormone synthesized from DHEA, is being explored for its potential role in androgen replacement therapy. Its usage is primarily focused on improving muscle mass, strength, and overall vitality, making it popular among athletes and bodybuilders. Though it is less commonly prescribed compared to other replacement therapies, the increasing interest in performance enhancement and anti-aging strategies is expanding the market for androstenedione therapy. Regulatory scrutiny and clinical guidelines will continue to shape its adoption and ensure safety in its application.

Methandrostenolone Replacement Therapy:

Methandrostenolone, commonly known as Dianabol, is primarily utilized in the bodybuilding community for its anabolic properties. It aids in muscle growth and strength enhancement, making it an appealing option for athletes. Although its use is often prohibited in competitive sports, the demand in non-competitive settings continues to influence its market presence. As awareness of the importance of safe usage and potential side effects increases, methandrostenolone therapy is expected to be regulated further, shaping its future in the androgen replacement market.

Mesterolone Replacement Therapy:

Mesterolone is another androgen supplement that is gaining attention for its potential benefits in treating testosterone deficiency. It is known for its relatively low androgenic activity compared to other testosterone derivatives, making it a favorable option for patients looking for milder options. Mesterolone is often used in conjunction with other therapies to enhance the overall treatment outcomes. The increasing acknowledgment of its therapeutic potential is driving its adoption, particularly among patients who wish to minimize the risk of side effects associated with stronger androgenic compounds.

By Application

Hypogonadism:

Hypogonadism, characterized by low testosterone levels, accounts for a significant portion of the androgen replacement therapy market. The increasing diagnosis rates of this condition, especially in aging males, are driving demand for testosterone replacement therapies. Men experiencing symptoms such as fatigue, depression, or reduced libido often seek medical advice, leading to a rise in prescriptions for testosterone therapy. The growing body of evidence supporting the benefits of hormone replacement in improving quality of life and mitigating health risks associated with hypogonadism is fostering market growth in this application segment.

Andropause:

Andropause, often referred to as male menopause, is characterized by a gradual decline in testosterone levels and can lead to various psychological and physical symptoms. The recognition of andropause as a legitimate medical condition has led to increased awareness and diagnosis, resulting in the escalation of consultations regarding androgen replacement therapy. Patients experiencing symptoms such as decreased libido, energy loss, and mood swings are increasingly turning to testing and treatment options. The growing acceptance of hormonal therapy in managing andropause symptoms is positively influencing the market segment associated with this application.

Delayed Puberty:

Delayed puberty in boys can be a challenging condition, often linked to low testosterone levels. Androgen replacement therapy is employed as a therapeutic intervention to stimulate puberty and promote appropriate development. The rising awareness and diagnosis of this condition among pediatric populations have resulted in an uptick in treatments prescribed to adolescents. Medical professionals are increasingly recognizing the importance of timely intervention, which further supports the growth of this market segment dedicated to delayed puberty applications.

Erectile Dysfunction:

Erectile dysfunction (ED) is another significant application area for androgen replacement therapy. Low testosterone levels are often implicated in causing or exacerbating ED, leading to an increased demand for testosterone therapy as a treatment option. The growing acceptance of the condition and the willingness to seek treatment are contributing to a robust market segment focused on addressing erectile dysfunction. With the rise in awareness regarding the importance of hormonal balance in sexual health, more men are exploring testosterone therapy as a solution to improve their sexual function.

Others:

The “Others” category encompasses various additional applications of androgen replacement therapy, including treatment for obesity-related hormonal imbalances and certain endocrine disorders. As research continues to uncover the roles of androgens in metabolic health and overall well-being, the market for alternative uses of androgen replacement therapy is anticipated to expand. Increased focus on holistic health approaches and comprehensive treatment plans is likely to foster growth in this segment as medical professionals explore diverse avenues for hormonal interventions.

By Distribution Channel

Hospitals:

Hospitals constitute a vital distribution channel for androgen replacement therapy, given their role as primary healthcare providers. Many patients diagnosed with testosterone deficiency receive treatment through hospital outpatient departments, where specialists can provide comprehensive evaluations and personalized treatment plans. The close monitoring of patients in hospital settings ensures the appropriate administration of therapy and minimizes potential side effects. The trend toward integrated healthcare services is further solidifying the hospital channel's importance as a trusted source for testosterone replacement therapies.

Clinics:

Clinics specializing in hormone therapy and men's health are experiencing rapid growth as distribution channels for androgen replacement therapy. These clinics provide focused care and cater specifically to the needs of patients seeking testosterone therapy. The personalized attention and expertise offered in these settings allow practitioners to tailor treatment plans effectively, enhancing patient satisfaction and adherence to therapy. As awareness of hormonal health continues to rise, clinics are becoming increasingly popular destinations for individuals seeking androgen replacement.

Retail Pharmacies:

Retail pharmacies serve as a crucial distribution channel, making androgen replacement therapies easily accessible to patients. The convenience of purchasing medications from local pharmacies, combined with the option for private consultations with pharmacists, is driving the growth of this segment. Additionally, retail pharmacies often stock a range of testosterone formulations, allowing patients to choose their preferred method of administration. The collaborative efforts between retail pharmacies and healthcare providers in managing patient therapy are enhancing the overall patient experience in accessing necessary medications.

Online Pharmacies:

Online pharmacies have emerged as a significant distribution channel for androgen replacement therapy, driven by the demand for convenience and accessibility. Patients are increasingly turning to online platforms for discreet consultations and prescriptions, especially for sensitive conditions like hypogonadism. The COVID-19 pandemic has accelerated the adoption of telehealth and online pharmacy services, enabling patients to receive their medications without the need for in-person visits. The flexibility and ease of ordering medications online are expected to foster further growth in this distribution channel.

Others:

The "Others" category encompasses various alternative distribution channels, including specialty pharmacies and compounding pharmacies, which offer tailored formulations of androgen replacement therapies. Specialty pharmacies often focus on specific patient needs, providing personalized services that enhance treatment adherence. Compounding pharmacies allow healthcare providers to customize dosages and formulations, catering to patients with unique requirements or sensitivities. As personalized medicine gains traction, these alternative distribution channels are likely to expand their role in delivering androgen replacement therapies.

By Ingredient Type

Testosterone:

Testosterone remains the leading ingredient in androgen replacement therapies, widely recognized for its effectiveness in treating testosterone deficiency. The various formulations, such as injections, patches, gels, and pellets, allow for versatile administration options tailored to patient preferences. The efficacy of testosterone in alleviating symptoms associated with low levels has made it the standard treatment for conditions like hypogonadism and andropause. Ongoing research into novel delivery methods and formulations continues to drive the market for testosterone-based therapies, ensuring their dominant position in the industry.

DHEA:

DHEA, or dehydroepiandrosterone, is gaining prominence as an alternative ingredient for androgen replacement therapies. As a naturally occurring hormone, DHEA serves as a precursor for both testosterone and estrogen, providing a more balanced approach to hormone replacement. Studies suggest that DHEA supplementation may be beneficial for improving energy levels, mood, and cognitive function. The growing body of evidence supporting the use of DHEA is expected to fuel its market presence as patients and healthcare providers explore this option as a potential alternative to traditional testosterone therapy.

Androstenedione:

Androstenedione, another steroid hormone, is used in specific applications within androgen replacement therapy, particularly for its anabolic properties. Although its use is less widespread than testosterone, the interest in androstenedione is particularly prominent among athletes and bodybuilders seeking performance enhancement. However, regulatory scrutiny surrounding its use in sports may impact its market trajectory, necessitating careful management of its therapeutic applications. Continued education about its benefits and potential risks will be crucial for its sustained presence in the market.

Methandrostenolone:

Methandrostenolone, known for its strong anabolic effects, is increasingly recognized within certain circles for its potential role in androgen replacement therapy. Its ability to promote significant muscle growth and strength makes it appealing, particularly among individuals interested in bodybuilding. However, due to its controversial status in competitive sports and potential side effects associated with misuse, its application must be approached with caution. Clear guidelines and education on safe usage will be essential for maintaining its legitimacy in therapeutic contexts.

Mesterolone:

Mesterolone, with its lower androgenic activity compared to other testosterone derivatives, offers a unique option for patients seeking androgen replacement therapy. It is often utilized in combination with other hormonal treatments to enhance overall therapeutic outcomes. The therapeutic profiles of mesterolone are being explored further, particularly in relation to its potential applications in managing low testosterone levels without the full intensity of stronger androgens. Its growing recognition in clinical settings underscores the evolving landscape of ingredient utilization in androgen replacement therapies.

By Region

The North American region is leading the global androgen replacement therapy market, accounting for over 40% of the market share in 2025. This dominance can be attributed to the high prevalence of testosterone deficiency, increased awareness among the aging population, and the presence of advanced healthcare infrastructure. The United States, in particular, has witnessed a significant rise in the acceptance of androgen replacement therapies, bolstered by educational campaigns from healthcare providers. The expected CAGR for the North American market is projected to be around 6.5%, indicating sustained growth as research and access to therapies continue to expand.

In Europe, the androgen replacement therapy market is experiencing growth driven by a similar aging demographic and increasing awareness surrounding hormonal health. The European market is projected to reach approximately USD 1.5 billion by 2035, capturing around 30% of the global market share. Countries such as Germany, France, and the United Kingdom are at the forefront of this growth, with healthcare systems supporting innovative treatments for testosterone deficiency. The European market is expected to witness a CAGR of 5.8% during the forecast period, as healthcare professionals advocate for hormonal therapies and patients increasingly seek treatment options.

Opportunities

The androgen replacement therapy market is presented with significant opportunities, particularly in the realm of personalized medicine. As healthcare continues to evolve towards individualized treatment plans, the development of tailored androgen therapies that cater to specific patient needs is gaining traction. Advances in genomic research and biomarker identification can pave the way for more effective therapies, improving patient outcomes and satisfaction. Moreover, the integration of telehealth services makes it easier for patients to receive consultations and prescriptions, further enhancing accessibility to and education about androgen replacement therapies. As awareness of hormone health continues to rise, more patients will seek these therapies, driving market growth.

Another essential opportunity lies in expanding market access to emerging economies, particularly in Asia Pacific and Latin America. These regions are experiencing demographic shifts and an increase in disposable incomes, fostering a growing demand for healthcare services, including hormone replacement therapies. As healthcare infrastructures improve and more healthcare professionals become trained in the management of testosterone deficiency, these markets are expected to see substantial growth. Collaborations between pharmaceutical companies and local healthcare providers can facilitate effective market entry and establish a firm presence in these rapidly developing regions.

Threats

Despite the promising outlook for the androgen replacement therapy market, certain threats could hinder its growth. The increasing scrutiny around the use of testosterone therapies, particularly in relation to potential side effects and health risks, has raised concerns among both patients and healthcare providers. Regulatory agencies are becoming more vigilant in monitoring the long-term effects of androgen replacement therapy, which could lead to tighter regulations and impact patient access. Furthermore, negative publicity surrounding testosterone therapy, stemming from concerns about misuse and over-prescription, may deter potential patients from seeking treatment.

In addition to regulatory challenges, the market faces competition from alternative treatment options, including lifestyle modifications and herbal supplements that are perceived as safer and more natural. Patients may gravitate towards these alternatives, particularly as public interest in holistic health approaches continues to grow. The rise of DIY healthcare practices, where individuals self-manage their hormone levels through unregulated products, poses another significant risk. These factors could contribute to a decline in patient adherence to prescribed androgen therapies and create barriers to market growth.

Competitor Outlook

• AbbVie Inc.
• Endo Pharmaceuticals Inc.
• Testosterone Replacement Therapy (TRT) by Clarus Therapeutics
• Ferring Pharmaceuticals
• Watson Pharmaceuticals Inc.
• Merck & Co., Inc.
• HRA Pharma
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Antares Pharma, Inc.
• GSK (GlaxoSmithKline)
• Pfizer Inc.
• Revive Therapeutics Ltd.
• Zynerba Pharmaceuticals, Inc.

The competitive landscape of the androgen replacement therapy market is marked by the presence of several key players, each vying for market share through innovative product offerings and strategic initiatives. Companies like AbbVie Inc. and Endo Pharmaceuticals Inc. lead the market with their robust portfolios of testosterone replacement therapies, providing a range of dosage forms that cater to diverse patient needs. The increasing focus on research and development, along with strategic partnerships and collaborations, plays a crucial role in driving innovation within the sector. As the demand for safe and effective androgen therapies rises, these companies are investing significantly in clinical trials to validate their products and expand their indications.

Moreover, the entry of niche players, such as Antares Pharma and Clarus Therapeutics, has introduced specialized formulations that address specific patient demographics and preferences. By leveraging advancements in drug delivery technologies, these companies are positioning themselves to provide tailored solutions that enhance patient adherence and satisfaction. The competitive landscape is also witnessing a trend towards consumer engagement strategies, where companies are educating patients about the benefits of therapy, thereby fostering a more informed patient population that actively seeks treatment options.

As the market evolves, larger pharmaceutical companies, such as Merck & Co., Inc. and Novartis AG, are also exploring opportunities in the androgen replacement therapy space through acquisitions and mergers. These strategic moves allow established players to expand their product ranges and enhance their market presence. Furthermore, collaborations with research institutions and healthcare providers are fostering innovation and facilitating the development of new therapies that meet emerging patient needs. The ongoing evolution of the competitive landscape signals a dynamic environment for androgen replacement therapy, where companies must remain agile to adapt to regulatory changes, patient preferences, and market trends.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 HRA Pharma
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Merck & Co., Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Antares Pharma, Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 GSK (GlaxoSmithKline)
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Ferring Pharmaceuticals
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Revive Therapeutics Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Endo Pharmaceuticals Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Watson Pharmaceuticals Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Zynerba Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Testosterone Replacement Therapy (TRT) by Clarus Therapeutics
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Androgen Replacement Therapy Market, By Application
    • 6.1.1 Hypogonadism
    • 6.1.2 ropause
    • 6.1.3 Delayed Puberty
    • 6.1.4 Erectile Dysfunction
    • 6.1.5 Others
  • 6.2 Androgen Replacement Therapy Market, By Product Type
    • 6.2.1 Testosterone Replacement Therapy
    • 6.2.2 DHEA Replacement Therapy
    • 6.2.3 rostenedione Replacement Therapy
    • 6.2.4 Methandrostenolone Replacement Therapy
    • 6.2.5 Mesterolone Replacement Therapy
  • 6.3 Androgen Replacement Therapy Market, By Ingredient Type
    • 6.3.1 Testosterone
    • 6.3.2 DHEA
    • 6.3.3 rostenedione
    • 6.3.4 Methandrostenolone
    • 6.3.5 Mesterolone
  • 6.4 Androgen Replacement Therapy Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Androgen Replacement Therapy Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Androgen Replacement Therapy market is categorized based on

By Product Type

• Testosterone Replacement Therapy
• DHEA Replacement Therapy
• rostenedione Replacement Therapy
• Methandrostenolone Replacement Therapy
• Mesterolone Replacement Therapy

By Application

• Hypogonadism
• ropause
• Delayed Puberty
• Erectile Dysfunction
• Others

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Testosterone
• DHEA
• rostenedione
• Methandrostenolone
• Mesterolone

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Endo Pharmaceuticals Inc.
• Testosterone Replacement Therapy (TRT) by Clarus Therapeutics
• Ferring Pharmaceuticals
• Watson Pharmaceuticals Inc.
• Merck & Co., Inc.
• HRA Pharma
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Amgen Inc.
• Antares Pharma, Inc.
• GSK (GlaxoSmithKline)
• Pfizer Inc.
• Revive Therapeutics Ltd.
• Zynerba Pharmaceuticals, Inc.